Novartis Ag

Sandoz Gmbh

Novartis Pharma Gmbh

Edwin Bernard Villhauer

Mahavir Prashad

Liladhar Murlidhar Waykole

Piotr Henryk Karpinski

Raeann Wu

Wolfgang Marterer

Bertrand Sutter

Denis Har

Jean-Claude Bianchi

Massimo Pignone

Eckart Buerger

Doris Stingelin

James Anthony Vivelo

Paul Allen Sutton

Thomas Edward Hughes

Michael John Girgis

Jessica Liang

Robert C Anderson

Howard C Smith

David G Holmes

James D Fraser

Gregory R Bebernitz

Jeffrey W Hughes

Boerk Balkan

David Grenville Holmes

Börk Balkan

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

Salts of aza-bicyclic di-aryl ethers and pharmaceuticals thereof

The present invention relates to novel crystalline forms of (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, sodium and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. It also relates to processes for making such novel crystalline forms.

Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid

The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.

Use of DPP-IV inhibitor to reduce hypoglycemic events

The invention discloses certain N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing said compounds as an active ingredient thereof, and the use of said compounds in inhibiting dipeptidyl peptidase-IV.

N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

The present invention relates to a compound of formula (I) ##STR1## wherein R is substituted adamantyl; and n is 0 to 3; in free form or in acid addition salt form. Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions

N-(N'-substituted glycyl)-2-cyanopyrrolidines of formula I ##STR1## wherein R is as defined herein. Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting

The invention discloses certain N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing said compounds as an active ingredient thereof, and the use of said compounds in inhibiting dipeptidyl peptidase-IV.

N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions

The invention discloses certain N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing said compounds as an active ingredient thereof, and the use of said compounds in inhibiting dipeptidyl peptidase-IV.

N-(substituted glycyl)-thiazolidines, pharmaceutical compositions

N-(N'-substituted glycyl)-2-cyanopyrrolidines of formula I ##STR1## Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

Compounds of the formula ##STR1## where X.sub.1 and X.sub.2 are independently O or S, and

Phosphinyloxy propanaminium inner salt derivatives

Growing community of inventors

East Hanover, NJ, United States of America

Edwin Bernard Villhauer